DSP Mutual Fund decreased its stake in IPCA Laboratories from 5.52% to 4.64% by selling 2,237,449 shares. The value of the sold shares is ₹429.69 crore at a price of ₹1920.40 apiece. This transaction takes DSP Mutual Fund below the 5% disclosure threshold.
A pharmaceutical manufacturer and marketer, Ipca Labs produces a wide range of medicines across therapeutic areas including antimalarials, anti-infectives, gastrointestinal treatments, and gynecological formulations. The company operates manufacturing facilities across India and exports its products to international markets. Its distinctive strength lies in its expertise in complex drug formulations, established distribution networks across Indian states, and a focus on affordable healthcare solutions for domestic and global markets.
Standalone AMC after DSP Group acquired full ownership from BlackRock in 2018. Manages over Rs 1.9 lakh crore. Known for equity funds with a clear process-first culture and minimal star manager dependency. CEO Kalpen Parekh is widely respected for transparent investor communication. DSP Small Cap Fund and DSP Midcap Fund are flagship offerings.
